Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A1 | P13866 | 2/20 | 0.36 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.36 |
| ▸ | TLR4 | O00206 | 2/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 10/20 | 0.35 |
| ▸ | SSTR3 | P32745 | 5/20 | 0.34 |
| ▸ | SSTR5 | P35346 | 5/20 | 0.34 |
| ▸ | SSTR2 | P30874 | 3/20 | 0.34 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7136893 | 0.95 | SLC5A1 (0.33) | SLC5A1SLC5A2TLR4CYP3A4MAPK1 | |
| SCHEMBL7144653 | 0.93 | TLR4 (0.36) | TLR4MCHR1SSTR3SSTR5SSTR2 | |
| SCHEMBL7137272 | 0.90 | TLR4 (0.35) | SLC5A1TLR4MCHR1SSTR3SSTR5 | |
| SCHEMBL7137280 | 0.90 | TLR4 (0.35) | SLC5A1TLR4MCHR1SSTR3SSTR5 | |
| SCHEMBL7133789 | 0.90 | TLR4 (0.34) | SLC5A1SLC5A2TLR4CYP3A4MAPK1 | |
| SCHEMBL7133793 | 0.90 | TLR4 (0.34) | SLC5A1SLC5A2TLR4CYP3A4MAPK1 | |
| SCHEMBL7141794 | 0.89 | TLR4 (0.35) | TLR4MCHR1SSTR3SSTR5SSTR2 | |
| SCHEMBL7144658 | 0.87 | TLR2 (0.36) | TLR4 | |
| SCHEMBL7141796 | 0.83 | TLR4 (0.32) | TLR4 | |
| SCHEMBL7136812 | 0.83 | TLR4 (0.34) | TLR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6511965-B2 | For therapy and prophylaxis of inflammatory disorders, autoimmune diseases or septicemia | SANKYO COMPANY, LIMITED (JP) | 2003-01-28 | — | — | US | disclosed |
| US-20020161221-A1 | Ether type lipid a 1-carboxylic acid analogs | SANKYO COMPANY, LIMITED (JP) | 2002-10-31 | — | — | US | disclosed |
| EP-1152007-A1 | ETHER TYPE LIPID A1-CARBOXYLIC ACID ANALOGUES | Sankyo Company, Limited (JP) | 2001-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161221-A1 | Ether type lipid a 1-carboxylic acid analogs | MSR1, ELOVL1, FFAR1 | SLC5A1 1006/4885SLC5A2 2011/4885TLR4 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.